RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Modified vaccinia ankara virus vaccination provides long-term protection against nasal rabbitpox virus challenge
Jones, D. I., McGee, C. E., Sample, C. J., Sempowski, G. D., Pickup, D. J., & Staats, H. F. (2016). Modified vaccinia ankara virus vaccination provides long-term protection against nasal rabbitpox virus challenge. Clinical and Vaccine Immunology, 23(7), 648-651. https://doi.org/10.1128/CVI.00216-16
Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
